This clinical trial is focused on studying the effects of a medication called Dexpramipexole (KNS-760704) on individuals with severe eosinophilic asthma. This type of asthma is characterized by high levels of a specific type of white blood cell called eosinophils, which can lead to more severe asthma symptoms. The study aims to evaluate how well Dexpramipexole can reduce severe asthma attacks over a period of 52 weeks.

Participants in the study will receive Dexpramipexole in the form of a film-coated tablet, which is taken orally. Some participants may receive a placebo, which looks like the medication but does not contain the active ingredient. The study will also involve other medications commonly used for asthma, such as Salbutamol and Budesonide/Formoterol, which are administered through inhalation. These medications help to open the airways and reduce inflammation, making it easier to breathe.

The trial will last for one year, during which participants will be monitored regularly to assess the safety and effectiveness of Dexpramipexole in managing severe eosinophilic asthma. The goal is to determine if this medication can help reduce the frequency and severity of asthma attacks, improve lung function, and enhance the overall quality of life for those affected by this condition.